Ian Reynolds manages Pew’s drug spending research initiative, which identifies policy options to help manage drug costs and ensure that patients have access to lifesaving treatments. Previously, he was an officer in Pew’s health group, where he led planning and development of new initiatives and coordinated the launch of projects.
Before joining Pew, Reynolds worked at Boston-based Community Catalyst to advance state and federal policies that improve conflict-of-interest standards in medicine and promote evidence-based practices. He also served as a Peace Corps volunteer in Turkmenistan, focusing on community health. Reynolds received a master of public health from Boston University and a bachelor’s degree from the University of Michigan.
Recent WorkView All
Rising drug costs remain top of mind for policymakers and payers, who continue to consider ideas to rein in spending at the state and national levels. From efforts intended to reduce out-of-pocket costs for patients to pending policy proposals from the Trump administration, here are some recent developments on this issue. Read More
Medicare Part D plans (PDPs) are required to cover at least two drugs in each therapeutic class, defined as a group of drugs used to treat the same disease or condition. However, for six therapeutic classes PDPs are required to cover “all or substantially all” drugs. These are known as the protected classes, and include antiretrovirals (used to treat HIV), immunosuppressants (when... Read More